Howard is an accomplished entrepreneur in the life sciences industry and prior to joining Seventh Sense, he was the founder, Chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company focused in the hospital critical care market. Mr. Weisman was also co-founder of ESP Pharma where he served as a director in addition to the company's President and COO until its sale to PDL Biopharma in 2005. He began his career in sales and marketing at Merck and Co, Inc. and later moved to Parke-Davis where he launched that company's diabetes franchise in 1997. Howard graduated with a BA in Chemistry from Rutgers University.
Howard is Chief Scientific Officer at Seventh Sense Biosystems. Dr. Bernstein has over 20 years of experience in microparticle/nanoparticle technology and drug development. He has been involved in the development of eight different nanoparticulate and microparticulate products including Nutropin Depot, which was the first sustained release product to be approved by the FDA. Before joining Seventh Sense, Dr. Bernstein was Executive Vice President of Research and Development at Acusphere, Inc. and prior to that, he was Vice President of Pharmaceutical Development at Alkermes. He holds 200 patents and patent applications. Dr. Bernstein received his Ph.D. in chemical engineering from MIT and his M.D. from Harvard Medical School through the MIT-Harvard Health Sciences and Technology program.
Don is Vice President of Engineering at Seventh Sense Biosystems. Before joining Seventh Sense, Dr. Chickering was Vice President of Technical Operations at Acusphere, Inc. Prior to that, he was Project Leader of the Therapeutic Delivery Systems group at Sulzer/Carbomedics. He has a total of 15 years experience in the areas of medical devices, microparticles, and drug delivery systems, and he holds over 30 US patents in these fields. Dr. Chickering was the recipient of the American Association of Medical Instrumentation Young Investigator Award and the Boston Business Journal's 40 Under 40 Award. He also served on the Northeastern University Industrial Advisory Board for the Chemical Engineering Department. Dr. Chickering has a B.S. in Biomedical Engineering from Rensselaer Polytechnic Institute and received his Ph.D. from Brown University's Department of Molecular Pharmacology and Biotechnology.